| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/14/2000 | DE19911097A1 Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen A process for the preparation of solid dosage forms cyclodextrin |
| 09/14/2000 | DE19907257A1 Mittel zur Steuerung der Diffusion von Injektionslösungen Means for controlling the diffusion of solutions for injection |
| 09/14/2000 | CA2371927A1 Nitric oxide manipulation of muscle satellite cell activation |
| 09/14/2000 | CA2367315A1 Apoptosis inducing molecule ii and methods of use |
| 09/14/2000 | CA2367144A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors |
| 09/14/2000 | CA2366719A1 Solubilization of polyunsaturated fatty acids and their derivatives by formation of inclusion complexes with y-cyclodextrin and their use in pharmaceutical, cosmetic or food compositions |
| 09/14/2000 | CA2366713A1 Antibody and chemokine constructs and their use in the treatment of autoimmune diseases |
| 09/14/2000 | CA2366689A1 Bifunctional molecules for delivery of therapeutics |
| 09/14/2000 | CA2365869A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
| 09/14/2000 | CA2365354A1 Methods and compositions for targeted drug delivery |
| 09/14/2000 | CA2364500A1 Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use |
| 09/14/2000 | CA2364444A1 Surface modification of lamellar particles |
| 09/14/2000 | CA2364442A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 09/14/2000 | CA2364253A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| 09/14/2000 | CA2363255A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 09/13/2000 | EP1035196A1 Improved pellet formulations |
| 09/13/2000 | EP1035144A2 Polyureas and watersoluble or waterdispersable polymeric salts |
| 09/13/2000 | EP1035137A1 Method for the reductive amination of polysaccharides |
| 09/13/2000 | EP1034839A1 Nanocapsules based on dendritic polymers |
| 09/13/2000 | EP1034795A2 Conjugates of lipids and biologically active compounds |
| 09/13/2000 | EP1034794A1 A formulation of dihydroartemisinin for the control of wide spectrum of malaria |
| 09/13/2000 | EP1034792A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 09/13/2000 | EP1034781A2 Oral adhesive sheet and oral adhesive preparation |
| 09/13/2000 | EP1034780A2 Betamethasone- and hyaluronic acid-treated thin adhesive plaster for the treatment of psoriasis, dermatitis and dermatosis |
| 09/13/2000 | EP1034207A1 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES |
| 09/13/2000 | EP1034180A2 Linker nucleoside, and production and use of the same |
| 09/13/2000 | EP1034007A1 A ONE DOSE SYRINGE, COMPRISING A FREEZE-DRIED PROTEIN COMPOSITION, FOR ADMINISTERING OF A VOLUME LESS THAN 0.5 ml |
| 09/13/2000 | EP1033999A1 Compositions of leukaemia inhibitory factor |
| 09/13/2000 | EP1033996A1 Prevention and treatment of amyloidogenic disease |
| 09/13/2000 | EP1033988A1 Parenteral formulations comprising carbamazepine or its derivatives |
| 09/13/2000 | EP1033983A1 Cyclic amino acid derivatives as cell adhesion inhibitors |
| 09/13/2000 | EP1033977A2 Pharmaceutical compositions having the shape of powders of cross-linked polymers loaded with drugs and related preparation process by supercritical fluids |
| 09/13/2000 | EP1033973A1 Encapsulation method |
| 09/13/2000 | EP1033972A1 Drug delivery system with two-step targeting |
| 09/13/2000 | EP1033971A1 Combined chemo-immunotherapy with liposomal drugs and cytokines |
| 09/13/2000 | EP1033970A1 Novel formulation for use in pain management |
| 09/13/2000 | EP1033969A1 Compositions adapted for prolonged residence in the nasal pharynx |
| 09/13/2000 | EP0729351B1 Vesicles with controlled release of actives |
| 09/13/2000 | EP0683664B1 Taxol formulation |
| 09/13/2000 | EP0652776B1 Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |
| 09/13/2000 | EP0586570B1 Backbone modified oligonucleotide analogues |
| 09/13/2000 | CN1266371A Stable insulin formulations |
| 09/13/2000 | CN1266370A Activated vitamin D3 emulsion-type lotions |
| 09/13/2000 | CN1266369A Dexamethasone gel |
| 09/13/2000 | CN1266081A Improved granular material formula |
| 09/13/2000 | CN1265922A Process for preparing calcium carboxymethyl cellulose |
| 09/13/2000 | CN1265884A Oral nifedipine pill and preparation process |
| 09/13/2000 | CN1265883A Base material of suppository |
| 09/13/2000 | CN1265882A Process for preparing medicinal granule |
| 09/13/2000 | CN1056413C New process for making crystalline sugar and products resulting therefrom |
| 09/13/2000 | CN1056277C Preparation process for tablet containing granule structure |
| 09/12/2000 | USRE36866 Anti-aids immunotoxins |
| 09/12/2000 | US6118043 Bone replacement material with FGF |
| 09/12/2000 | US6117982 Microbead coupled with binding molecules which lack fc portions and are specific for cd2, cd3 or other t cell receptor-linked components, cd4, cd5 or cd8; anticarcinogenic agents and treatment of infections |
| 09/12/2000 | US6117980 Humanized anti-IL-8 monoclonal antibodies |
| 09/12/2000 | US6117949 Water solubility at low temperature; drug delivery |
| 09/12/2000 | US6117864 Methods employing stable preparation containing azelastine hydrochloride |
| 09/12/2000 | US6117858 For specific delivery of biologically active substances to achieve lower doses and for improved efficacy with drugs such as oligonucleotides and polynucleotides with problems in achieving therapeutic concentrations at targeted organs |
| 09/12/2000 | US6117857 Pharmaceutical composition |
| 09/12/2000 | US6117655 Nucleic acid encoding adhesion variants |
| 09/12/2000 | US6117454 Loading a nanoparticle with a drug, coating with polyoxyethylene glycol, sorbitan monosteare or monooleate, or monolaurate, or monopalmitate, administering to the mammal in such a manner which allows it to enter the bloodstream |
| 09/12/2000 | US6117442 A core comprising androgen as a therapeutical agent and an elastomeric membrane encasing the core comprising polysiloxane containing 3,3,3 trifluoropropylgroup attached to silicon atom of siloxane unit |
| 09/12/2000 | US6117441 Silicone core long term androgen delivery implant |
| 09/12/2000 | US6117434 Humectant composition, base containing the same, and cosmetic material or external preparation containing said humectant composition |
| 09/12/2000 | US6117433 Use of compositions comprising stabilized biologically effective compounds |
| 09/12/2000 | US6117425 Supplemented and unsupplemented tissue sealants, method of their production and use |
| 09/12/2000 | CA2212794C Oil in water emulsions containing propofol and edetate |
| 09/12/2000 | CA2064476C Podophyllotoxin preparation containing triglycerides |
| 09/08/2000 | WO2000052049A2 A method for purifying human growth hormone |
| 09/08/2000 | WO2000052037A1 Echinocandin/carbohydrate complexes |
| 09/08/2000 | WO2000051718A1 Chemical method for making pyrithione particle dispersions |
| 09/08/2000 | WO2000051645A1 Polymer compositions for polynucleotide delivery |
| 09/08/2000 | WO2000051644A1 TREATMENT OF DIARRHEA CAUSED BY ENTEROPATHOGENIC $i(ESCHERICHIA COLI) |
| 09/08/2000 | WO2000051643A1 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| 09/08/2000 | WO2000051629A1 Preparations stabilized over long time |
| 09/08/2000 | WO2000051626A1 Chemically modified g-csf preparations |
| 09/08/2000 | WO2000051603A2 Compositions of remifentanil |
| 09/08/2000 | WO2000051576A2 Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain |
| 09/08/2000 | WO2000051572A1 Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| 09/08/2000 | WO2000051570A1 Chewable soft capsules having improved administration properties and process for producing the same |
| 09/08/2000 | WO2000051568A1 Orally dispersible tablet with low friability and method for preparing same |
| 09/08/2000 | WO2000051563A1 Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter |
| 09/08/2000 | WO2000023592B1 Minimal promoters and uses thereof |
| 09/08/2000 | WO2000010526A3 New oral formulation for 5-ht4 agonists or antagonists |
| 09/08/2000 | WO1999064595A9 THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME |
| 09/08/2000 | WO1999049019A8 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 09/08/2000 | CA2366318A1 Novel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid |
| 09/08/2000 | CA2364063A1 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| 09/08/2000 | CA2364030A1 A method for purifying human growth hormone |
| 09/08/2000 | CA2364006A1 Polymer compositions for polynucleotide delivery |
| 09/08/2000 | CA2363983A1 Chemical method for making pyrithione particle dispersions |
| 09/08/2000 | CA2362480A1 Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter |
| 09/08/2000 | CA2362016A1 Echinocandin/carbohydrate complexes |
| 09/08/2000 | CA2359754A1 Treatment or diarrhea caused by enteropathogenic escherichia coli |
| 09/07/2000 | DE19929647A1 Nifedipine pellets providing both rapid and sustained release comprise particulate core and nifedipine coating |
| 09/06/2000 | EP1033132A1 Rapidly soluble drug composition |
| 09/06/2000 | EP1032675A1 Attaching substances to micro-organisms |
| 09/06/2000 | EP1032659A1 Grafted copolymers as gene carriers |
| 09/06/2000 | EP1032647A1 Preservation of sensitive biological samples by vitrification |
| 09/06/2000 | EP1032592A1 Antimicrobial peptides |